Should aerobic first or resistance first? Comparison of concurrent training sequence on metabolic risk in type 2 diabetes (systematic review and network meta-an

This summary is based on a network meta-analysis that included 27 randomized controlled trials (total n=965) comparing two sequences in concurrent training—"aerobic→resistance" (CART) versus "resistance→aerobic" (CRAT). The results indicate that both sequences improved multiple cardiometabolic indicators compared with control, but the current certainty of evidence is low and it is not possible to determine that one is clearly superior to the other [1].

Study type: Journal Article,Network Meta-Analysis,Systematic Review (classification: Clinical guideline / high-quality systematic review) Published: Endocrine, 2026-09-28 Source: PubMed public abstract

This summary is based on a network meta-analysis that included 27 randomized controlled trials (total n=965) comparing two sequences in concurrent training—"aerobic→resistance" (CART) versus "resistance→aerobic" (CRAT). The results indicate that both sequences improved multiple cardiometabolic indicators compared with control, but the current certainty of evidence is low and it is not possible to determine that one is clearly superior to the other [1].

Why this study matters

Why this question is important

Concurrent training (combining aerobic and resistance training) is commonly recommended in exercise prescriptions for type 2 diabetes (T2DM) to improve glycemia and cardiovascular metabolic risk. In clinical practice and population health promotion, a practical question arises: does performing aerobic before resistance (CART) versus resistance before aerobic (CRAT) lead to different metabolic effects? Li et al. conducted a systematic review and network meta-analysis addressing this question, synthesizing randomized controlled trials up to January 2026 [1].

What the study actually found

Associations reported by the study (based only on the abstract results)

• The network meta-analysis included 27 randomized controlled trials, totaling 965 participants; search date through January 2026 [1].
• Compared with control, both CART (aerobic→resistance) and CRAT (resistance→aerobic) produced significant improvements in multiple cardiometabolic markers, including body fat percentage, HbA1c, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein (abstract reports p < 0.05) [1].
• In unadjusted SUCRA (ranking probability) analyses, CRAT ranked higher for body composition, glycemic control, insulin resistance, and most lipid items; CART ranked higher for systolic and diastolic blood pressure [1].
• Sensitivity analyses indicated: intervention duration influenced body composition rankings; participant sex influenced blood pressure rankings. Further meta-regression suggested age may modify the relative effects of the two sequences on BMI, HbA1c, and blood pressure, indicating participant characteristics and training factors may affect outcomes [1].
• The authors noted that many direct comparisons were non-significant, and using CINeMA they judged overall evidence certainty as low, so current evidence does not support definitively recommending one sequence over the other; more head-to-head trials are needed to clarify differences [1].

Possible implications for CKD, dialysis, or transplant patients

Conclusions with sufficient evidence / interpretations that can be cautiously adopted

• It is reasonable to interpret that concurrent aerobic and resistance training benefits multiple cardiometabolic risk markers in patients with type 2 diabetes, and both sequence arrangements can lead to improvements (the abstract reports both were significantly better than control) [1].
• However, there is insufficient and inconsistent evidence to recommend one specific sequence as superior; SUCRA rankings are exploratory, and the authors emphasize these rankings are unadjusted and of low certainty, so interpret with caution [1].

More high-quality, direct-comparison trials are needed to confirm whether clinically important sequence differences exist and which patient characteristics (age, sex, intervention duration, etc.) modify effects.

Limitations of the current research

Study limitations (important—please note)

• This summary is based on the authors’ reported results in the abstract of the systematic review and network meta-analysis. If the full text is not available, details (such as training volume, frequency, intensity, participants’ baseline characteristics, follow-up time, non-glycemic safety outcomes) cannot be examined. This piece was written based on the PubMed public abstract and the full text was not read.
• The authors state in the abstract that most direct comparisons were non-significant and that CINeMA rated the overall certainty as "low," indicating uncertainty and risk of bias in the evidence, so no definitive conclusions can be drawn.
• SUCRA rankings are unadjusted order probabilities and may be influenced by heterogeneity, covariates, and study quality. The abstract did not present full trial details, limiting generalizability and individualized recommendations [1].
• Unreported or insufficiently described training details (e.g., intensity, total workload, level of supervision) and participant comorbidities (such as chronic kidney disease, transplant status, concurrent medications) may affect external applicability, but the abstract does not provide adequate information to assess these aspects.

Conclusions that remain uncertain

Unproven hypotheses and unresolved questions (require further research)

• Whether there is a clinically meaningful optimal sequence (CART vs CRAT): the abstract shows ranking differences, but due to low certainty and non-significant direct comparisons, one sequence cannot be declared superior to the other [1].
• Which patient characteristics modify sequence effects: exploratory analyses suggest age, sex, and intervention duration may influence results, but these remain hypothesis-generating and require formal stratified or interaction testing.
• Long-term clinical outcomes and safety: the current focus is on short- to mid-term metabolic marker improvements; effects on long-term cardiovascular events, complications, or exercise-related adverse events are not reported in the abstract.
• Importance of training prescription details: whether intensity, frequency, session order, and total load are more important than the simple order of modalities remains unclear; more RCTs directly comparing different training parameters are needed.

(The above is based only on the abstract report and does not represent a full-text analysis.)

Questions to discuss with your medical team

• This analysis says concurrent training is beneficial, but is it safe for me personally (I have multiple chronic conditions or take medications)? How should I discuss an exercise plan with my medical team?
• Will my age or sex change the benefits I get from CART or CRAT? Do I need individualized sequencing?
• Are training intensity, frequency, or session workload more important than training sequence? How should I ask an exercise instructor about training specifics?
• If I want to apply the training approaches reported in the studies to daily life, what monitoring or clinical follow-up (e.g., blood glucose, blood pressure) should I discuss with my physician?
• Are there high-quality long-term RCTs directly comparing CART and CRAT? If not, what future studies might provide clearer guidance?

How to read this study (our interpretation)

This section was written by the Beyond CKD editor — a kidney-transplant recipient with a health-management background, not a physician — using only the PubMed abstract. We have not read the full paper, and no clinician has reviewed this text. It is meant to help you understand the numbers, not to advise treatment.

What the study asked

Exercise advice for type 2 diabetes usually means “aerobic plus resistance training”, but does the order within a session matter? This network meta-analysis pooled 27 randomised trials with 965 participants and compared aerobic-then-resistance (CART) with resistance-then-aerobic (CRAT) for body fat, blood sugar, lipids and blood pressure.

How to read the results

Both orders clearly beat non-exercising controls on body-fat percentage, HbA1c, fasting glucose, total cholesterol, triglycerides and LDL (all p < 0.05) — that is the most solid finding. For which order is better, the authors used SUCRA rankings: resistance-first ranked higher for body composition, glycaemic control, insulin resistance and most lipids; aerobic-first ranked higher for systolic and diastolic blood pressure. But SUCRA is only a probability ranking; the direct comparisons between the two orders were not significant, and the authors state plainly that these results are exploratory, do not support recommending one order, and that certainty (CINeMA) is low.

Limitations

Fewer than a thousand people spread across 27 trials means each comparison rests on small numbers. Rankings shifted with training duration, sex and age, which signals instability. The abstract does not report intensity, weekly frequency or follow-up length.

What it means for readers and people with kidney disease

If you have diabetes or metabolic syndrome, the dependable takeaway is that combined aerobic and resistance training works and the order matters little — start with whichever you are more likely to keep doing. If you also have CKD, exercise type and intensity still need to account for blood pressure, potassium, bone health and dialysis scheduling, none of which this review covers.

How to check further

Ask your doctor or physiotherapist: Given my kidney function and blood pressure, what weights and repetitions are sensible? Are there glucose or potassium issues to watch before and after sessions?

Original abstract: PubMed 42804093 (https://pubmed.ncbi.nlm.nih.gov/42804093/). Interpretation last updated 2026-11-06.

References

[1] Li Z, Liu C, Liu Y. Effects of concurrent training sequence on cardiometabolic risk factors in patients with type 2 diabetes: a systematic review and network meta-analysis.. Endocrine. 2026. DOI: 10.1007/s12020-026-04775-5. PMID: 42804093.

Medical disclaimer: This article is for general health education and information only. It does not constitute individual medical diagnosis, treatment advice, or a doctor–patient relationship. Medical research is continually updated, and study findings have their own scope and limitations. Every patient's condition, laboratory values, medications and treatment needs differ. Do not stop or adjust medication doses, change your diet or fluid intake, or alter dialysis or transplant treatment based on this article alone. For any medical questions, please consult your nephrologist or another qualified healthcare professional.

Article created: 2026-10-31 | Original study published: 2026-09-28 | Last checked: 2026-10-31 (source metadata verified with PubMed)